Abiraterone Impurities

Abiraterone is a potent selective inhibitor of CYP17A1, an enzyme essential for androgen biosynthesis. By targeting CYP17A1, Abiraterone effectively blocks the production of androgens in the testes, adrenal glands, and within tumor cells, making it a critical treatment for metastatic castration-resistant prostate cancer (mCRPC). Its mechanism involves dual inhibition of 17α-hydroxylase and 17,20-lyase activities, leading to decreased testosterone levels, which helps suppress the progression of androgen-dependent tumors. Typically administered with corticosteroids like prednisone, Abiraterone reduces the risk of side effects associated with mineralocorticoid excess, including hypertension and fluid retention. It has demonstrated significant survival benefits in advanced prostate cancer, revolutionizing treatment protocols. Abiraterone is also a valuable compound for biochemical research and drug development targeting androgen receptor signaling pathways.